Optimizing Treatment Patterns in Relapsed or Refractory Diff

A panel of head and neck cancer experts discussed the nuances of managing relapsed or refractory DTC with lenvatinib or sorafenib, as well as sequencing considerations with targeted therapies in the second-line setting and beyond for patients with relapsed or refractory disease.

Related Keywords

Ezra Cohen , Marcias Brose , Eli Lilly , Francesp Worden , Lorij Wirth , Eisai Inc , Onclive Peer Exchange , National Comprehensive Cancer Network , Novartis Pharmaceuticals Corp , During The Peer Exchange , Blueprint Medicines Corp , Bayer Healthcare Pharmaceuticals Inc , Genentech Inc , Onclive Peer , Peer Exchange , Metab Clin North , Healthcare Pharmaceuticals Inc , Medicines Corp , Pharmaceuticals Corp , Practice Guidelines ,